Beijing Hotgen Biotech Co., Ltd. (SSE Code: 688068) will participate in ADLM 2026 and showcase its innovative immunodiagnostic solutions at Booth 4020. As an innovative company dedicated to the in vitro diagnostics (IVD) field, Hotgen is committed to providing clinical laboratories and healthcare institutions with accurate and efficient diagnostic solutions through advanced technologies.
Founded in 2005, Hotgen continuously advances innovation in immunodiagnostics based on eight proprietary technology platforms. The company has established a comprehensive product portfolio centered on chemiluminescence immunoassay, complemented by point-of-care testing (POCT) and rapid testing products, providing diversified diagnostic solutions for various healthcare scenarios worldwide.
At ADLM 2026, Hotgen will showcase the following innovative products:
- MQ60 Series Mono-test Chemiluminescence Immunoassay System: As one of Hotgen’s flagship products, the MQ60 Series delivers accurate, efficient, and reliable testing performance. With more than 18,000 cumulative installations worldwide and a menu of over 130 testing parameters, the system meets the needs of clinical laboratories of different sizes for high-quality immunodiagnostic testing.
- C800 and C2100 Series Chemiluminescence Immunoassay Systems: Designed to address the testing requirements of healthcare institutions with different scales, these systems provide flexible, efficient, and reliable automated chemiluminescence immunoassay solutions.
- UPT2800 Point-of-Care Testing System: Powered by Hotgen’s proprietary Up-converting Phosphor Technology (UPT), the system features rapid, accurate, and portable testing capabilities, supporting applications in primary healthcare, emergency diagnostics, and public health testing.
- TB-IGRA Tuberculosis Infection Detection Solution: Designed for tuberculosis infection screening and clinical auxiliary diagnosis, providing reliable testing support for global tuberculosis prevention and control.
In addition, Hotgen will showcase its colloidal gold rapid testing products and ELISA product portfolio, further meeting diverse diagnostic needs across different healthcare institutions and application scenarios.
Currently, Hotgen’s products are available in more than 50 countries and regions and have obtained international certifications, including CE IVDR (Europe), supporting the global adoption of high-quality immunodiagnostic solutions.
We warmly welcome ADLM 2026 attendees to visit Hotgen at:
Booth 4020
Connect with our team to explore innovative immunodiagnostic technologies and discover the future of laboratory solutions